Microsoft Word Kurzweil, Ray The Singularity Is Near doc

Circulation
103.25 (June 26, 2001): 3047–50. 
39.
S. E. Nissen et al., "Effect of Recombinant Apo A-I Milano on Coronary Atherosclerosis in 
Patients with Acute Coronary Syndromes: A Randomized Controlled Trial," 
JAMA
290.17 
(November 5, 2003): 2292–2300. 
40.
A recent phase 2 study reported "markedly increased HDL cholesterol levels and also decreased 
LDL cholesterol levels," M. E. Brousseau et al., "Effects of an Inhibitor of Cholesteryl Ester 
Transfer Protein on HDL Cholesterol," 
New England Journal of Medicine
350.15 (April 8, 2004): 
1505–15, http://content.nejm.org/cgi/content/abstract/350/15/1505. Global phase 3 trials began in 
late 2003. Information on Torcetrapib is available on the Pfizer site: 
http://www.pfizer.com/are/investors_reports/annual_2003/review/p2003ar14_15.htm. 
41.
O. J. Finn, "Cancer Vaccines: Between the Idea and the Reality," 
Nature Reviews: Immunology
3.8 
(August 2003): 630–41; R. C. Kennedy and M. H. Shearer, "A Role for Antibodies in Tumor 
Immunity," 
International Reviews of Immunology
22.2 (March–April 2003): 141–72. 
42.
T. F. Greten and E. M. Jaffee, "Cancer Vaccines," 
Journal of Clinical Oncology
17.3 (March 
1999): 1047–60. 
43.
"Cancer 'Vaccine' Results Encouraging," BBCNews, January 8, 2001, 
http://news.bbc.co.uk/2/hi/health/1102618.stm, reporting on research by E. M. Jaffee et al., "Novel 
Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for 
Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation," 
Journal of Clinical 
Oncology
19.1 (January 1,2001): 145–56. 
44.
John Travis, "Fused Cells Hold Promise of Cancer Vaccines," March 4, 2000, 
http://www.sciencenews.org/articles/20000304/fob3.asp, referring to D. W. Kufe, "Smallpox, Polio 
and Now a Cancer Vaccine?" 
Nature Medicine
6 (March 2000): 252–53. 
45.
J. D. Lewis, B. D. Reilly, and R. K. Bright, "Tumor-Associated Antigens: From Discovery to 
Immunity," 
International Reviews of Immunology
22.2 (March–April 2003): 81–112. 
46.
T. Boehm et al., "Antiangiogenic Therapy of Experimental Cancer Does Not Induce Acquired Drug 
Resistance," 
Nature
390.6658 (November 27,1997): 404–7. 
47.
Angiogenesis Foundation, "Understanding Angiogenesis," 
http://www.angio.org/understanding/content_understanding.html; L. K. Lassiter and M. A. 
Carducci, "Endothelin Receptor Antagonists in the Treatment of Prostate Cancer," 
Seminars in 
Oncology
30.5 (October 2003): 678–88. For an explanation of the process, see the National Cancer 
Institute Web site, "Understanding Angiogenesis," 
http://press2.nci.nih.gov/sciencebehind/angiogenesis/angio02.htm. 
48.
I. B. Roninson, "Tumor Cell Senescence in Cancer Treatment," 
Cancer Research
63.11 (June 1, 
2003): 2705–15; B. R. Davies et al., "Immortalization of Human Ovarian Surface Epithelium with 
Telomerase and Temperature-Sensitive SV40 Large T Antigen," 
Experimental Cell Research
288.2 
(August 15, 2003): 390–402. 

---

49.
See also R. C. Woodruff and J. N. Thompson Jr., "The Role of Somatic and Germline Mutations in 
Aging and a Mutation Interaction Model of Aging," 
Journal of Anti-Aging Medicine
6.1 (Spring 
2003): 29–39. See also notes 18 and 19. 
50.
Aubrey D. N. J. de Grey, "The Reductive Hotspot Hypothesis of Mammalian Aging: Membrane 
Metabolism Magnifies Mutant Mitochondrial Mischief," 
European Journal of Biochemistry
269.8 
(April 2002): 2003–9; P. F. Chinnery et al., "Accumulation of Mitochondrial DNA Mutations in 
Ageing, Cancer, and Mitochondrial Disease: Is There a Common Mechanism?" 
Lancet
360.9342 
(October 26, 2002): 1323–25; A. D. de Grey, "Mitochondrial Gene Therapy: An Arena for the 
Biomedical Use of Inteins,"